Emerging Role of Biologics for the Treatment of Melioidosis and Glanders
| Autor: | Javier I. Sanchez-Villamil, Daniel Tapia, Alfredo G. Torres |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Melioidosis Genus Burkholderia Burkholderia pseudomallei medicine.drug_class Clinical Biochemistry Antibiotics Burkholderia mallei Article 03 medical and health sciences 0302 clinical medicine Drug Discovery medicine Animals Humans Intensive care medicine Pharmacology Biological Products biology business.industry Glanders medicine.disease biology.organism_classification 030104 developmental biology Burkholderia 030220 oncology & carcinogenesis business |
| Zdroj: | Expert Opin Biol Ther |
| Popis: | Introduction: Two important pathogenic species within the genus Burkholderia, namely Burkholderia pseudomallei (Bpm) and Burkholderia mallei (Bm), are the causative agents of the life-threatening diseases melioidosis and glanders, respectively. Due to their high mortality rate and potential for aerosolization, they have gained interest as potential biothreat agents and are classified as Tier 1 Select Agents.Areas covered: The manuscript provides an overview of the literature covering the efforts taken in the last 10 years to develop new therapeutics measures against both Bpm and Bm, with attention on novel therapeutic agents.Expert Opinion: As a result of the complicated antibiotic regimens necessary to treat these infections, development of novel therapeutics is needed to treat both diseases. In recent years, the understanding of the pathogenesis of Burkholderia has improved significantly and so have the efforts to develop novel therapeutic agents with high efficacy, either alone, or in combination with conventional antibiotics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|